Carlsbad, CA — January 16, 2026 — Leads & Copy — Palisade Bio, Inc. (Nasdaq: PALI) announced that two abstracts highlighting its lead program, PALI-2108, have been selected for poster presentation at two premier international inflammatory bowel disease (IBD) meetings in early 2026.
The clinical-stage biopharmaceutical company is developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon.
Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio, said the abstract acceptances underscore the growing scientific and clinical interest in PALI-2108 and its differentiated, gut-targeted approach to treating ulcerative colitis. Jones added that he looks forward to engaging with the global IBD community and discussing these translational findings across two leading GI forums.
PALI-2108 is an orally administered prodrug engineered for local delivery of phosphodiesterase-4 (PDE4) inhibition to the terminal ileum and colon. The prodrug molecule is gut-restricted and pharmacologically inactive until it reaches the lower intestine, where it is cleaved by bacterial enzymes to release its active PDE4 inhibitor metabolite directly at the site of inflammation and fibrosis.
Palisade Bio is advancing a next-generation oral PDE4 inhibitor prodrugs designed to improve pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases. The Company’s lead program, PALI-2108, is being developed for moderate-to-severe Ulcerative Colitis (UC) and fibrostenotic Crohn’s Disease (FSCD), two diseases with limited non-immunosuppressive therapy options.
In a recently reported Phase 1b trial, PALI-2108 achieved a 100% clinical response in the UC cohort, with no serious adverse events, favorable tolerability and pharmacokinetics consistent with localized activation in the lower intestine, low systemic exposure, and controlled release within the GI tract.
Palisade Bio is advancing towards a Phase 2 clinical study in UC designed to evaluate clinical remission, response and pharmacodynamic biomarkers over 12 weeks, with an extension phase assessing maintenance of remission. In addition, the Company is preparing to initiate studies in FSCD to further characterize PALI-2108’s safety, pharmacology and therapeutic benefit across inflammatory bowel disease indications.
Participation details are as follows:
Crohn’s & Colitis Congress® 2026
January 22–24, 2026 | Las Vegas, NV
Poster Presentation
Session: Poster Hall Reception
Date & Time: Friday, January 23, 2026, 5:00 PM – 6:30 PM PT
Title: PALI-2108, a Colon-Targeted PDE4B Inhibitor, Rapidly Restores Immune-Epithelial Balance in Ulcerative Colitis Through Gut-Selective Lymphocyte Depletion
Presenter: James Izanec, MD, AGAF, VP, Head of Clinical Development, Palisade Bio
21st Congress of ECCO – Inflammatory Bowel Diseases 2026
February 18–21, 2026 | Stockholm, Sweden
Poster Presentation
Session: Guided Poster Session
Date & Time: Friday, February 20, 2026, 12:40 – 13:40 CET
Location: Poster Exhibition Hall A
Poster Number: P0989
Title: Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Translational Findings from a Phase 1a Study
Presenter: James Izanec, MD, AGAF, VP, Head of Clinical Development, Palisade Bio
Jenene Thomas
908-824-0775
PALI@jtcir.com
Source: Palisade Bio
